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Abstract
Aims/hypothesis—Resistin is a peptide hormone produced by adipocytes that is present at high
levels in sera of obese mice and may be involved in glucose homeostasis through regulation of insulin
sensitivity. Several studies in humans have found associations between polymorphisms in the resistin
gene and obesity, insulin sensitivity and blood pressure. An association between variation in the
resistin gene and Type 2 diabetes has been reported in some, but not all studies. The aim of this study
was to analyse variants of the resistin gene for association with Type 2 diabetes and related traits in
a Finnish sample.
Methods—In 781 cases with Type 2 diabetes, 187 spouse controls and 222 elderly controls of
Finnish origin, we genotyped four previously identified non-coding single-nucleotide
polymorphisms (SNPs): −420C>G from the promoter region, +156C>T and +298G>A from intron
2, and +1084G>A from the 3′ untranslated region. We then tested whether these SNPs were
associated with Type 2 diabetes and related traits.
Results—The SNPs were not significantly associated with Type 2 diabetes. However, SNPs
−420C>G, +156C>T and +298G>A and the common haplotype for these three markers were
associated with increased values of weight-related traits and diastolic blood pressure in cases, lower
weight in elderly control subjects, and lower insulin sensitivity and greater acute insulin response in
spouses. Furthermore, the +1084G allele was associated with lower HDL cholesterol in both cases
and controls, higher systolic blood pressure and waist circumference in cases, and greater acute
insulin response in spouse controls.
Conclusions/interpretation—Our results add to growing evidence that resistin is associated with
variation in weight, fat distribution and insulin resistance.
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Introduction
Type 2 diabetes is caused by poor pancreatic beta cell function on a background of insulin
resistance. Obesity, especially abdominal and visceral obesity, is commonly associated with,
and may cause, insulin resistance in Type 2 diabetes. Signalling molecules secreted by adipose
tissue may provide the link between insulin resistance and obesity, and resistin is one such
molecule [1]. In murine models, resistin is induced during adipocyte differentiation and its
expression decreases upon treatment with insulin sensitizers. Serum levels of resistin are
elevated in obese mice, both when the obesity is genetic and when it is the result of a high-fat
diet, and administration of resistin impairs glucose tolerance in normal mice. This suggests
that resistin links obesity to insulin resistance and Type 2 diabetes [1]. However, other studies
of rat and mouse models have associated insulin resistance and obesity with decreased resistin
expression [2,3]. It has recently been reported that mice lacking the resistin gene resemble
normal mice in most respects, including body weight, but have better glucose tolerance that
stems from reduced hepatic glucose production [4]. Among mice on high-fat diets, the
relationship between body weight and blood glucose is weaker in mice lacking resistin than in
normal mice, suggesting that the effects of resistin may be mediated by diet and obesity [4].
Human studies have found no relationship between resistin expression and insulin resistance
or adiposity [5,6,7], although one study found that resistin mRNA expression decreased during
adipogenic differentiation [5]. One possible explanation for these seemingly contradictory
findings is that resistin expression may be inhibited by insulin and other factors related to
obesity [8,9]. Alternatively, resistin may block adipose tissue formation [10], leading to insulin
resistance due to a lack of fresh, insulin-sensitive adipocytes [11].
Although the role of resistin in the pathogenesis of Type 2 diabetes has not been fully
established, its potential importance is supported by studies of variation in the human resistin
gene. Non-coding variants of the gene have been identified [12,13,14,15,16,17,18,19,20,21,
22] and have been shown to be associated with variables related to weight [12,13], insulin
[14,15] and blood pressure [16]. A recent study reported that a polymorphism in the promoter
region was associated with resistin mRNA levels in abdominal subcutaneous fat [12].
Associations between resistin polymorphisms and Type 2 diabetes have been reported in some
studies [16,17], but not others [13,14,18,19,20]. In the present study we genotyped four variants
of the resistin gene that have shown evidence of association with Type 2 diabetes-related traits
[12,13,14,15,16] and tested whether these single-nucleotide polymorphisms (SNPs) were
associated with Type 2 diabetes and related quantitative traits.
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The study group was a Finnish cohort of 781 Type 2 diabetes cases and 409 control subjects
from the Finland–United States Investigation of NIDDM Genetics (FUSION) Study (http://
fusion.sph.umich.edu) [23]. The FUSION study was designed to identify genetic variants that
predispose individuals to Type 2 diabetes and influence intermediate quantitative traits in the
Finnish population. The study design and details regarding the determination of diabetes status
and diabetes-related traits have been described previously [23]. Cases were unrelated
individuals with Type 2 diabetes, almost all from families with at least two recruited Type 2
diabetes siblings. Controls were 187 normoglycaemic spouses of Type 2 diabetes cases and
222 unrelated subjects who had normal glucose tolerance according to OGTTs performed at
the ages of 65 and 70 years (elderly controls). Cases, normoglycaemic spouses, and elderly
controls are further described elsewhere [24]. Excluded from analysis were: (i) cases who had
a first-degree relative with Type 1 diabetes; (ii) cases with uncertain diabetes status; and (iii)
cases who took medication expected to influence the traits of interest on the day of examination.
Cases were receiving treatment for Type 2 diabetes in the form of diet and, for the majority of
subjects, some combination of insulin and oral medication. The majority of cases and control
subjects could be characterised as hypertensive, and most of these individuals were being
treated with anti-hypertensive drugs. About 30% of cases and controls were also treated with
lipid-lowering drugs. Characteristics of the study subjects, including the rates of different types
of treatment and prevalence of hypertension, are summarised in Table 1. Informed consent was
obtained from each study participant, and all protocols were approved by the Ethics Committee
or Institutional Review Board at each of the participating centres.
Genotyping.
We genotyped four previously identified non-coding SNPs: −420C>G (rs1862513) from the
promoter region [12,13,14,15,17], +156C>T (rs3219177) [13,14,15,17,18,21] and
+298G>A (rs3745367) [14,17,18,19] from intron 2, and +1084G>A (rs3745368) from the 3′
untranslated region (UTR) on exon 4 [16,21] of the resistin gene on chromosome 19. These
four SNPs were chosen because they had shown evidence of association with Type 2 diabetes-
related traits in other study samples [12,13,14,15,16]. The SNPs had an allele frequency of
>0.1 in Caucasians, and comprised four of the six common (>0.1) variations identified in
previous studies that screened both coding and regulatory regions of the gene for
polymorphisms [13,14,15,17,18,20,21]. In order to identify any additional SNPs in coding
regions, we screened 760 bp of the promoter region and all four exons in 94 individuals of
Finnish origin; however, we found no additional variants with an allele frequency of >0.1
[22]. The SNPs were genotyped by homogeneous MassEXTEND reaction using the
MassARRAY System (Sequenom, San Diego, Calif., USA) as previously described [25].
Assay details are available from the authors upon request. There were 5644 successful
genotypes out of the 5756 attempted (98.1%). Among 324 blinded duplicate genotype pairs,
one discrepancy was observed. The genotype frequencies of all four SNPs were in Hardy–
Weinberg equilibrium.
Haplotype assignment.
Haplotype frequencies were estimated by the EM algorithm [26] and were used to estimate
linkage disequilibrium (LD) between markers. Individual haplotypes were assigned as the pair
of haplotypes with the maximum posterior probability computed from the estimated haplotype
frequencies. Haplotypes were assigned if the maximum posterior probability exceeded 0.9,
which was true in all cases. A probability cut-off point of 0.99 resulted in the exclusion of 43
individuals (3.6% of our sample) but did not yield any meaningful differences in the results.
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In the results reported here, we used 0.9 as our cut-off point, which allowed us to use the entire
sample.
Association analyses.
Associations between Type 2 diabetes and SNPs and haplotypes were assessed using chi square
tests of independence and logistic regression adjusting for age and sex. Association tests were
performed for: (i) the entire sample; (ii) the control group restricted to either spouses or elderly
controls; and (iii) individuals with BMI <30, BMI ≥30 and BMI ≥35.
Associations between quantitative traits and SNPs and haplotypes were tested using ANOVA
with adjustment for age and sex. Additional tests with adjustment for BMI were performed for
the non-weight-related traits. We assumed that the alleles acted additively, hence all of our
ANOVA models included the number of copies of the allele or haplotype as a covariate. Traits
were transformed to approximate normality when necessary.
We analysed fourteen traits for all subjects: BMI, WHR, waist circumference, weight at
enrolment, self-reported maximum lifetime weight, fasting plasma glucose, fasting serum
insulin, total cholesterol, HDL cholesterol, HDL cholesterol : total cholesterol ratio, LDL
cholesterol, total triglycerides and systolic and diastolic blood pressure. We measured and
analysed three additional traits for Type 2 diabetes subjects and spouse controls: self-reported
weight at age 20 years, weight change since age 20 years (enrolment weight−weight at 20
years), and maximum lifetime weight change since age 20 years (maximum lifetime weight
−weight at 20). We measured and analysed fasting C-peptide concentrations for cases alone,
and 2-h glucose and insulin levels for controls alone. We analysed insulin sensitivity (SI),
glucose effectiveness (SG), acute insulin response to glucose (AIR), and the disposition index
(DI=SI×AIR) for spouse controls who underwent a tolbutamide-modified frequently sampled
intravenous glucose tolerance test.
Because of the large number of comparisons (a total of 18 for cases, 23 for spouses and 16 for
elderly controls) we performed permutation tests to estimate the probability of observing a
similar number of associated traits due to chance alone. For each study group (cases, spouses,
and elderly control subjects), we created 10,000 permuted samples by randomly shuffling
genotypes across the sample (leaving the vector of correlated traits, including sex and age,
intact). For each permuted sample, we performed ANOVA tests of association for all traits.
We then compared the pattern of trait associations in the permuted samples to the original
cluster of traits significant at the 0.05 level. We computed the overall p value for each study
group as the proportion of permuted samples having at least as many traits with p values less




Allele frequencies for the four SNPs did not differ significantly between Type 2 diabetes cases
and the combined controls (Table 2), nor were there significant differences when subjects were
stratified by BMI or when the control group was restricted to spouses or elderly controls
(p>0.15).
Haplotype analysis.
Three of the four SNPs (−420C> G, +156C>T, and +298G>A) had similar minor allele
frequencies of ~0.25 and were in strong LD, with R2≈0.8. These SNPs formed two predominant
haplotypes: CCG (72%) and GTA (22%). The minor allele of SNP +1084G>A was rarer, with
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a frequency of 0.02, and did not appear in either of the major haplotypes. Frequencies of the
common haplotypes were not significantly different between cases and controls (data not
shown).
Trait associations.
Table 3 shows the mean values for significantly associated traits (p<0.05, adjusted for sex and
age) for subjects with 0, 1 or 2 copies of the common CCG haplotype (means for all traits can
be found in Table 1 of the Electronic Supplementary Material [ESM]). Among Type 2 diabetes
cases, increasing copy numbers of the CCG haplotype were associated with increased waist
circumference (p=0.001), weight (p=0.005), weight change since age 20 years (p=0.005),
WHR (p=0.007), diastolic blood pressure (p=0.016) and BMI (p=0.019). However, among
elderly controls, increasing CCG copy numbers were associated with decreased weight
(p=0.032). For spouse controls, additional copies of CCG were associated with lower SI
(p=0.013) and greater AIR (p=0.016), two traits that were not measured in cases and elderly
controls. Adjustment for BMI where appropriate had no effect on the observed pattern of trait
associations; consequently, only sex- and age-adjusted p values are reported in Table 3. The
three SNPs forming the CCG haplotype were also tested individually and had extremely similar
patterns of associated traits (data not shown). Among 10 000 permuted samples of cases, only
20 samples had six or more traits associated with a p value of less than or equal to 0.019,
indicating that the observed cluster of associated traits is unlikely to be due to chance alone
(p=0.002). For elderly controls (p=0.338) and spouses (p=0.097), the observed associations
could be explained by chance.
Table 4 presents mean trait values by genotype for all traits that were significantly associated
(p<0.05) with the 3′ UTR SNP (+1084G>A) (means for all traits are reported in Table 2 of the
ESM). Type 2 diabetes subjects with G/G rather than A/G genotypes had higher systolic blood
pressures (p=0.024) and mean waist circumferences (p=0.026) and lower levels of HDL
cholesterol (p=0.040). Elderly controls with the G/G genotype had lower HDL cholesterol
(p=0.006) and HDL : total cholesterol ratios (p=0.032). Among spouse controls, G/G subjects
had significantly lower HDL cholesterol (p=0.005) and greater AIR (p=0.003), weight change
(p=0.041) and DI (p=0.041) than A/G subjects. Again, adjusting for BMI in addition to sex and
age did not change the observed pattern of trait associations. Permutation tests showed that for
each of the three groups tested, the probability of observing at least as many associated traits
due to chance exceeded 0.05 but was still suggestive (0.076 for cases, 0.125 for elderly controls
and 0.063 for spouses). The two most significant traits for spouses (AIR and HDL) had p values
less than or equal to 0.005, which would only be expected by chance 2.5% of the time.
Cases received treatment for Type 2 diabetes in the form of diet, medication and insulin, and
many subjects were hypertensive or were taking other medications that could affect the traits
studied (see Subjects and methods section and Table 1). In order to verify that these inter-
subject differences were not responsible for the observed trait associations, we tested whether
the resistin variants were associated with hypertension, treatment for hypertension and
dyslipidaemia or type of treatment for diabetes. No significant associations were found,
indicating that the trait associations described above were not simply artefacts of associations
of resistin with other diseases or with type of treatment.
Discussion
Our results provide evidence that variants in the resistin gene are related to obesity and insulin
resistance. The CCG haplotype formed by SNPs −420C>G, +156C>T and +298G>A was
associated with increased adiposity and weight gain during adult life in cases and with increased
insulin resistance in spouse controls; however, CCG was associated with lower body weight
in elderly controls. The seemingly contradictory results for these SNPs are not unique to the
Conneely et al. Page 5













FUSION study. Of the five studies that have analysed SNP −420C>G [12,13,14,15,17], three
reported significant associations with quantitative traits, all in non-Type 2 diabetes subjects.
In two studies, the C allele was associated with reductions in weight-related variables [12,
13]. In a third study, the C/C genotype of SNP −420C>G was associated with reduced SI, and
the C/C genotypes of both SNP −420C>G and SNP +156C>T were associated with reduced
SI in interaction with BMI [14]. In a functional study, the G/G genotype of SNP −420C>G
was associated with greater promoter activity in adipocytes and, among 58 overweight and
obese subjects, resistin mRNA was present in abdominal subcutaneous fat at significantly
higher levels in G/G homozygotes [12]. Together, these findings suggest a complex
relationship between the resistin genotype and phenotypes related to insulin reistance and
obesity.
Whether the complex and sometimes contradictory findings in this study and others are the
result of interactions with other genes or environmental factors that differ between cases and
controls remains to be determined. Environmental factors such as treatment could pose serious
problems in studies of this kind. As documented in the Results section, the resistin variants
studied here were not associated with the type of treatment for Type 2 diabetes, hypertension,
or medication for hypertension or dyslipidaemia. Since none of these factors were associated
with the SNPs in this study, they are probably not responsible for the associations observed.
However, environmental factors that affect the phenotypes studied are likely to reduce the
power to detect association in general and could explain why certain traits are associated with
variation in the resistin gene in some studies but not others. Meta-analyses or studies with
larger sample sizes may be necessary to resolve the complicated and often contradictory pattern
of traits associated with resistin variants.
Another reason for trait associations that differ between specific groups of cases and controls
could be that the important variant is in LD with different alleles of the same SNP for different
groups. Since all of the SNPs studied here are in regulatory regions, it is possible that they act
as proxies for an undetected coding SNP, or perhaps another regulatory SNP. SNP
−420C>G has been shown to be associated with levels of resistin mRNA in overweight subjects
[12], which may suggest that the variant of interest is in the promoter. Additional screening
for regulatory variants would help to resolve this issue, as would functional studies of these
variants.
We observed several associations with phenotypes other than obesity and insulin resistance.
Diastolic blood pressure increased with the number of copies of the CCG haplotype in Type 2
diabetes cases. Systolic blood pressure was elevated in cases with the G/G genotype at SNP
+1084G>A. In both instances, the genotype associated with higher blood pressure was also
associated with greater obesity in cases, suggesting that the effect of genotype on blood pressure
may be mediated by obesity. For SNP +1084G>A, HDL cholesterol was lower in subjects with
the G/G genotype in all study groups, but G/G was not consistently associated with increased
weight. This suggests that variants in the resistin gene could affect HDL metabolism directly
or through factors other than obesity.
The lack of an association between resistin genotypes and Type 2 diabetes may reflect the
dependence of the pathogenesis of diabetes on dual defects in insulin resistance and insulin
secretion [27]. In non-Type 2 diabetes subjects, obesity and insulin resistance are normally
balanced by increased insulin secretion [27,28]. The associations between CCG and low SI
and high AIR in spouse controls may be a manifestation of this phenomenon. Genes that
promote insulin resistance in certain individuals may provide a background in which Type 2
diabetes can develop, while other genes may determine whether an individual cannot maintain
high levels of insulin secretion and thus develops Type 2 diabetes on that background. Our
failure to find associations between Type 2 diabetes and variants in the resistin gene could
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suggest that resistin plays a role in determining the insulin resistance background but has little
impact on insulin secretion or beta cell function. However, our analysis of the DI (assessed
only in spouse controls), which is used as an indicator of the ability of beta cells to compensate
for insulin resistance, did yield marginal evidence of an association.
In conclusion, our results from a sample of Finnish Type 2 diabetes cases and controls provide
evidence that non-coding variants in the resistin gene are associated with variation in obesity
and insulin resistance, which are two traits that predispose individuals to Type 2 diabetes.
Associations were also found between the SNPs and blood pressure and HDL cholesterol, traits
that have been related to insulin resistance and obesity in many studies. These results suggest
that variation in the resistin gene is probably not directly involved in the beta cell dysfunction
that causes Type 2 diabetes; however, it may play an important role in the pathogenesis of
obesity and insulin resistance on which Type 2 diabetes develops.
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Table 1







Sex (M:F) 435:346 61:126 107:115
Age at enrolment (years) 63.9±7.5 61.7±7.8 70.0±0.3
Age at diagnosis (years) 50.9±8.3 – –
Diabetes duration (years) 13.1±7.4 – –
BMI (kg/m2) 29.9±4.6 28.5± 4.5 27.1±4.0
Fasting plasma glucose (mmol/l) 10.3±3.3 5.3± 0.7 5.0±0.5
Fasting serum insulin (pmol/l) 114.7±95.7 76.9± 49.8 65.3±32.5
Treated for T2D with insulin (%) 48.0 – –
Treated for T2D with tablets (%)a 67.2 – –
Treated for T2D with diet only (%) 7.8 – –
Hypertension (%)b 80.1 66.7 64.6
Treated with anti-hypertensive drugs (%) 71.6 50.4 48.3
Treated with counteracting lipids (%) 30.1 33.9 29.4
Values are means ± SD or percentages.
a
Treatment with sulphonylureas or metformin;
b
individuals were characterised as hypertensive if they met at least one of the following criteria: (i) systolic blood pressure ≥160 mm Hg; (ii) diastolic
blood pressure ≥95 mm Hg; or (iii) receiving treatment with antihypertensive drugs. T2D: Type 2 diabetes
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Table 2
Allele counts and frequencies among Type 2 diabetes cases and control subjects
Allele counts/total (frequency)
SNP Allele Cases Controls p valuea Adjusted p
valueb
−420C>G G 423/1564 (0.27) 219/818 (0.26) 0.89 0.97
+156C>T T 368/1590 (0.23) 190/824 (0.23) 0.96 0.99
+298G>A A 402/1586 (0.25) 205/826 (0.24) 0.78 0.77
+1084G>A A 31/1550 (0.02) 17/806 (0.02) 0.86 0.56
a
Based on chi square test of independence;
b
based on logistic regression, adjusted for age and sex
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Table 3
Traits associated with the CCG haplotype
Number of copies of the CCG haplotype
Trait 0 1 2 p valuea
Type 2 diabetes cases n=67 n=305 n=405
 Waist circumference (cm) 99.5±8.5 101.3±10.8 103.4±12.6 0.001
 Weight (kg) 80.8±10.1 83.2±14.1 84.8±15.0 0.005
 Weight change (kg)b 16.4±10.8 19.5±11.9 21.1±14.2 0.005
 WHR 0.936±0.064 0.942±0.068 0.948±0.079 0.007
 Diastolic BP (mm Hg) 82.2±10.3 84.5±10.3 85.2±10.5 0.016
 BMI (kg/m2) 29.1±3.6 29.5±4.5 30.4±4.7 0.019c
Elderly control subjects n=17 n=97 n=107
 Weight (kg) 80.4±17.1 75.1±13.5 73.5±11.9 0.032d
 Maximum weight (kg) 84.5±18.8 78.6±13.7 77.6±12.8 0.051
Spouse control subjects n=12 n=74 n=101
 SI (×10
5 min−1· [pmol/l]−1) 8.27±6.78 6.47±3.48 5.23±2.60 0.013
 AIR (pmol/l×8 min) 1656±614 2223±1665 2479±1696 0.016e
Values are means ± SD. For data on all traits tested, please see ESM Table 1.
a
Based on a test of effects of the number of copies of the CCG haplotype on the normal-transformed value of the trait, adjusted for age and sex;
b
current weight minus self-reported weight at age 20 years;
c
probability of observing at least six traits with p≤0.019 in Type 2 diabetes cases is 0.002 (estimated from permutation test);
d
probability of observing at least one trait with p≤0.032 in elderly control subjects is 0.338 (estimated from permutation test);
e
probability of observing at least two traits with p≤0.016 in spouse controls is 0.097 (estimated from permutation test)
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Table 4
Traits associated with SNP +1084G>A
Genotype at +1084G>A
Trait A/G G/G p valuea
Type 2 diabetes cases n=31 n=742
 Systolic BP (mm Hg) 143±14 153±22 0.024
 Waist circumference (cm) 99.2±8.3 102.4±11.8 0.026
 HDL cholesterol (mmol/l) 1.20±0.30 1.10±0.31 0.040b
 HDL : total cholesterol ratio 0.219±0.053 0.200±0.064 0.051
Elderly control subjects n=8 n=208
 HDL cholesterol (mmol/l) 1.78±0.46 1.40±0.30 0.006
 HDL : total cholesterol ratio 0.281±0.063 0.237±0.052 0.032c
Spouse control subjects n=9 n=178
 AIR (pmol/l×8 min) 944±805 2403±1653 0.003
 HDL (mmol/l) 1.67±0.31 1.31±0.36 0.005d
 Weight change (kg)e 10.0±7.4 16.8±11.0 0.041
 DI 6184±4949 12503±8985 0.041f
Values are means ± SD. For data on all traits tested, please see ESM Table 2.
a
based on a test of effects of the presence of the minor allele on the normal-transformed value of the trait, adjusted for age and sex;
b
probability of observing at least three traits with p≤0.040 in Type 2 diabetes cases is 0.076 (estimated from permutation test);
c
probability of observing at least two traits with p≤0.032 in elderly control subjects is 0.125 (estimated from permutation test);
d
probability of observing at least two traits with p≤0.005 in spouse controls is 0.025 (estimated from permutation test);
e
current weight minus self-reported weight at age 20 years;
f
probability of observing at least four traits with p≤0.041 in spouse controls is 0.063 (estimated from permutation test)
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